Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Stetler-Stevenson Website

William G. Stetler-Stevenson, M.D., Ph.D.

Selected Publications

1)  Han H, Bourboulia D, Jensen-Taubman S, Isaac B, Wei B, Stetler-Stevenson WG.
An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells.
Oncogene. [Epub ahead of print], 2013.
2)  Bourboulia D, Han H, Jensen-Taubman S, Gavil N, Isaac B, Wei B, Neckers L, Stetler-Stevenson WG.
TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells.
Oncotarget. 4: 163-73, 2013.
3)  Adamson A, Ghoreschi K, Rittler M, Chen Q, Sun HW, Vahedi G, Kanno Y, Stetler-Stevenson WG, O'Shea JJ, Laurence A.
Tissue inhibitor of metalloproteinase 1 is preferentially expressed in Th1 and th17 T-helper cell subsets and is a direct stat target gene.
PLoS ONE. 8: e59367, 2013.
4)  Kim SH, Cho YR, Kim HJ, Oh JS, Ahn EK, Ko HJ, Hwang BJ, Lee SJ, Cho Y, Kim YK, Stetler-Stevenson WG, Seo DW.
Antagonism of VEGF-A-induced increase in vascular permeability by an integrin a3ß1-Shp-1-cAMP/PKA pathway.
Blood. 120: 4892-902, 2012.
5)  Stetler-Stevenson W, Bourboulia D, Guedex L, Jensen-Taubman S.
Anti-tumoral Properties of Endogenous Angiogenesis Inhibitors: A Case for Continued TIMP-2 Preclinical Development.
Curr. Angiogenesis. 1: 148-56, 2012.
6)  Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, Neckers L.
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells.
Cell Cycle. 11: 3649-55, 2012.
7)  Gonçalves AN, Meschiari CA, Stetler-Stevenson WG, Nonato MC, Alves CP, Espreafico EM, Gerlach RF.
Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli.
J. Biotechnol. 157: 20-4, 2012.
8)  Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG.
Matrix metalloproteinases: changing roles in tumor progression and metastasis.
Am. J. Pathol. 181: 1895-9, 2012.
9)  Bourboulia D, Jensen-Taubman S, Stetler-Stevenson W.
TIMP-2 An Endogenous Angiogenesis Inhibitor with Distinct Antitumoral Properties.
Treat. Strategies Hematol. 2: 31-35, 2012.
10)  Guedez L, Jensen-Taubman S, Bourboulia D, Kwityn CJ, Wei B, Caterina J, Stetler-Stevenson WG.
TIMP-2 Targets Tumor-associated Myeloid Suppressor Cells With Effects in Cancer Immune Dysfunction and Angiogenesis.
J. Immunother. 35: 502-12, 2012.
Click Here to View Expanded Bibliography.

This page was last updated on 5/1/2013.